These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 8769208)

  • 21. Pharmacokinetics of a microemulsion formulation of cyclosporine in pediatric liver transplant recipients.
    Cooney GF; Lum BL; Meligeni JA; Dunn SP
    Transplant Proc; 1996 Aug; 28(4):2270-2. PubMed ID: 8769222
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of Neoral and Sandimmune preparations in renal transplant patients--improved pharmacokinetics with neoral.
    Warrens AN; Salama A; Waters JB; Lechler RI
    Transplant Proc; 1996 Aug; 28(4):2169-70. PubMed ID: 8769190
    [No Abstract]   [Full Text] [Related]  

  • 23. Successful reconversion from tacrolimus to cyclosporine A Neoral in pediatric liver recipients.
    Melter M; Rodeck B; Kardorff R; Hoyer PF; Maibücher A; Brodehl J
    Transplant Proc; 1996 Aug; 28(4):2276-8. PubMed ID: 8769224
    [No Abstract]   [Full Text] [Related]  

  • 24. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation.
    McVicar JP; Kowdley KV; Emond MJ; Barr D; Marsh CL; Carithers RL; Perkins JD
    Clin Transplant; 1997 Aug; 11(4):328-33. PubMed ID: 9267724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and tolerability of Neoral in transplant recipients.
    Feutren G; Wong R; Jin J; Niese D; Mellein B
    Transplant Proc; 1996 Aug; 28(4):2177-82. PubMed ID: 8769193
    [No Abstract]   [Full Text] [Related]  

  • 26. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss.
    Bahra M; Neumann UP; Jacob D; Langrehr JM; Neuhaus P
    Transplant Proc; 2005 May; 37(4):1700-2. PubMed ID: 15919436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical results of quadruple drug immunosuppression in liver transplantation.
    Fabregat J; Fradera R; Jaurrieta E; Figueras J; Rafecas A; Rufi G; Casanovas T; Casais L; Gil Vernet S
    Transplant Proc; 1992 Feb; 24(1):148-9. PubMed ID: 1539217
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunosuppressive requirements for small bowel/liver transplantation.
    McAlister V; Grant D; Wall W; Roy A; Ghent C; Zhong R; Duff J
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1204-5. PubMed ID: 8442086
    [No Abstract]   [Full Text] [Related]  

  • 29. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation.
    Lange D; Bechstein WO; Blumhardt G; Lemmens P; Schattenfroh N; Neuhaus P
    Transplant Proc; 1993 Apr; 25(2):1870-1. PubMed ID: 8470207
    [No Abstract]   [Full Text] [Related]  

  • 30. Experience with neoral cyclosporine through the oral route in liver transplantation.
    Bilbao I; Lazaro JL; Pou L; Charco R; Hildalgo E; Murio E; Margarit C
    Transplant Proc; 1998 Jun; 30(4):1432-4. PubMed ID: 9636580
    [No Abstract]   [Full Text] [Related]  

  • 31. Potential role of Neoral in pediatric liver transplantation.
    Whitington PF; Alonso EM; Millis JM
    Transplant Proc; 1996 Aug; 28(4):2267-9. PubMed ID: 8769221
    [No Abstract]   [Full Text] [Related]  

  • 32. Neoral conversion study: shift from Sandimmune classic formulation to Neoral in heart and lung transplant patients.
    Svendsen UG; Larsen KR; Allermand H; Thayssen P; Jensen SB; Pettersson G
    Transplant Proc; 1996 Aug; 28(4):2281. PubMed ID: 8769225
    [No Abstract]   [Full Text] [Related]  

  • 33. Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients.
    Platz KP; Tullius SG; Mueller AR; Schumacher G; Nüssler N; Neuhaus R; Bechstein WO; Lobeck H; Neuhaus P
    Transplant Proc; 1996 Dec; 28(6):3183-4. PubMed ID: 8962235
    [No Abstract]   [Full Text] [Related]  

  • 34. Hepatic allograft rejection under quadruple immunosuppressive regimen with cyclosporine A in liver transplantation: incidence of viral and fungal infection.
    Fabregat J; Fradera R; Figueras J; Rafecas A; Torras J; Martinez LaCasa J; Baliellas C; Casais L; Jaurrieta E
    Transplant Proc; 1994 Oct; 26(5):2697-9. PubMed ID: 7940845
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
    White M; Pelletier GB; Tan A; Jesina C; Carrier M
    J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Limited sampling strategy to estimate exposure to cyclosporine A in renal allograft recipients treated with Sandimmune-Neoral.
    Serafinowicz A; Gaciong Z; Baçzkowska T; Rell K; Lao M; Wałaszewski J
    Transplant Proc; 1996 Dec; 28(6):3138-9. PubMed ID: 8962216
    [No Abstract]   [Full Text] [Related]  

  • 37. Conversion from Sandimmune to Neoral in stable renal transplant recipients. Sandoz Study Group OLN-353.
    Pescovitz MD
    Transplant Proc; 1996 Aug; 28(4):2196-8. PubMed ID: 8769198
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacokinetic analysis of Neoral conversion in pediatric and adult renal transplant recipients with poor absorption of Sandimmune.
    Pescovitz MD; Henson S; Bodziak K; Book BK; Gonin J; Jindal RM; Leapman SB; Milgrom ML; Filo RS
    Transplant Proc; 1996 Aug; 28(4):2165-8. PubMed ID: 8769189
    [No Abstract]   [Full Text] [Related]  

  • 39. Neoral in liver transplantation.
    Jamieson NV; Tan L; Jamieson I; Trull A; Gimson AE; Alexander G; Friend PJ; Calne RY
    Transplant Proc; 1996 Aug; 28(4):2229-31. PubMed ID: 8769207
    [No Abstract]   [Full Text] [Related]  

  • 40. Neoral therapy in liver transplantation.
    Levy GA
    Transplant Proc; 1996 Aug; 28(4):2225-8. PubMed ID: 8769206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.